Investigation
Ginkgo Bioworks
- Risk Level
- HIGH
- Label
- Red Flagged
- Jurisdictions
- United States (Boston, MA HQ)
- Period
- 2021 – 2025
- Verified Filings Reviewed
- 24+
- Tagged
- Jason Kelly
ⓘ Weighted Risk Indicators
Ginkgo Bioworks
NYSE-listed synthetic biology platform company (ticker: DNA) operating autonomous lab and cloud lab services from Boston, Massachusetts, accused of inflating foundry revenue through systematic related-party transactions with entities it created, funded, or managed.
Ginkgo Bioworks (NYSE: DNA) is a Boston-based synthetic biology platform company whose foundry revenue model has been the subject of significant fraud allegations since 2021, when short-seller Scorpion Capital characterized the company as a 'colossal scam' built on round-trip revenue from entities Ginkgo itself created, funded, or managed.
Following the report's publication, Ginkgo's stock declined approximately 12%, multiple securities fraud class actions were filed, and the company disclosed in November 2021 that the U.S. Department of Justice had opened an inquiry into the underlying allegations. While Ginkgo's internal investigation concluded the allegations were 'unfounded,' the company subsequently agreed in 2025 to a $2.75 million settlement of derivative actions arising from the same conduct.
The combination of an unresolved federal inquiry, a financial settlement of shareholder claims, and persistent transparency gaps regarding the identity and arm's-length nature of foundry counterparties — including affiliated brands such as Ginkgo Ferment and Grow by Ginkgo — sustains a HIGH composite risk profile across regulatory, financial-disclosure, and governance dimensions.
Verified Identity
Professional Timeline
Ginkgo Bioworks Holdings, Inc.
United States
Ginkgo Ferment
United States
Grow by Ginkgo
United States
Unnamed Ginkgo-Created/Funded Counterparties
Unknown
Identified Entities & Relationships
Relationship Map
Click any entity card to view detailed information.
AML Risk Indicators
Allegation that the majority of reported foundry revenue derives from entities Ginkgo itself created, funded, or managed — combined with non-disclosure of counterparty identities — creates significant revenue-quality and securities-disclosure risk.
Relationship Types
Undisclosed / Unverified Relationships
• Identity of foundry customers Ginkgo allegedly created, funded, or managed
• Capital flow structure between Ginkgo and affiliated brands Ginkgo Ferment and Grow by Ginkgo
• Ownership and governance overlap with the 130+ claimed customers
Active DOJ Inquiry & Settled Shareholder Litigation
The U.S. Department of Justice opened an inquiry in November 2021 into allegations of revenue manipulation and related-party transactions. The company subsequently settled derivative shareholder actions in 2025 for $2.75 million without admission of liability. The current status of the DOJ inquiry remains undisclosed.
Securities Fraud Class Action (2021)
Filed by multiple law firms on behalf of shareholders following the Scorpion Capital report and 12% stock decline; resolved through subsequent settlements.
Derivative Actions Settlement (2025)
Ginkgo Bioworks agreed to pay $2.75 million to settle derivative shareholder claims relating to revenue manipulation and related-party transaction allegations.
DOJ Inquiry — November 2021
Pending / UndisclosedFederal inquiry into revenue recognition and related-party transaction allegations; status undisclosed.
Select an event to view details
Voices from the Record
"A colossal scam built on phantom revenue from entities Ginkgo itself created, funded, or managed."
— Scorpion Capital, 2021 short report
"The Company has received an inquiry from the U.S. Department of Justice."
— Ginkgo Bioworks public disclosure, November 2021
12%
Approximate same-day stock decline following the Scorpion Capital report.
No material DMCA-driven content suppression has been identified relating to coverage of the Scorpion Capital report or subsequent litigation; adversarial research and press coverage remain publicly accessible.
Employer Sentiment: Mixed Signals
Public employee review platforms reflect mixed sentiment — strength on technical mission and Boston facilities is offset by recurring commentary on commercial execution and post-de-SPAC strategic uncertainty.
Ginkgo's owned media emphasizes its autonomous lab platform, AI-enabled developability services, and 130+ customer claim. The promotional narrative does not address the unresolved DOJ inquiry, the $2.75 million derivative settlement, or the substance of related-party transaction allegations — a material asymmetry between marketing posture and disclosed legal exposure.
Verified facts include the DOJ inquiry, the $2.75M derivative settlement, and the post-report stock decline. The most consequential allegations — majority related-party foundry revenue and round-trip cash flows — remain disputed, with the company denying misconduct while resolving private claims financially.
Digital Footprint
Corporate Channels & Investor Communications
Ginkgo maintains an active corporate web presence and investor relations channel emphasizing platform capabilities, AI services, and customer count. Public communications during and after the 2021 allegations focused on rebutting the Scorpion Capital report; subsequent settlement-related communications have been limited to required regulatory disclosures.
Website Evolution (2021–2025)
The corporate site has shifted emphasis over time from a foundry-cells-engineered narrative toward AI-enabled services (antibody developability, HTS, perturbation profiling) and the Catalyst Agent autonomous lab system. The 2025 iteration foregrounds Ginkgo Solutions and Ginkgo Datapoints product lines while maintaining the 130+ customer claim.
Community Intelligence
Investor and biotech-analyst communities continue to debate Ginkgo's revenue quality, with bull-case narratives focused on platform potential and bear-case threads referencing the Scorpion Capital thesis, the DOJ inquiry, and the 2025 derivative settlement.
Scorpion Capital Report Published
Short-seller publishes 'colossal scam' report alleging majority related-party foundry revenue.
Stock Drops ~12%
Shares decline approximately 12% in response to the short-seller report.
Securities Class Actions Filed
Multiple law firms file securities fraud class actions on behalf of shareholders.
DOJ Inquiry Disclosed
Ginkgo discloses receipt of a U.S. Department of Justice inquiry into the allegations.
Internal Investigation Concluded
Company-led internal review concludes allegations are 'unfounded.'
Derivative Settlement
Ginkgo agrees to a $2.75 million settlement of derivative actions without admission of liability.
Continued Operations
Company continues active operations, marketing 130+ customers and Catalyst Agent platform.
Overall Risk Score
6.7/10
The following areas could not be fully verified and represent limitations of this investigation:
- Current status and scope of the DOJ inquiry opened in November 2021 are not publicly disclosed.
- Identities and ownership structures of alleged Ginkgo-controlled or Ginkgo-funded counterparties remain unmapped.
- Detailed methodology and evidentiary basis of Ginkgo's internal investigation that concluded allegations were 'unfounded' have not been published.
- Independent audit-grade reconciliation of foundry revenue between independent and related counterparties is unavailable.
- Governance and capital-flow relationships between Ginkgo and affiliated brands (Ginkgo Ferment, Grow by Ginkgo) are not transparently disclosed.
- Final disposition of any SEC review parallel to the DOJ inquiry, if any, remains unconfirmed.
Ginkgo Bioworks presents a HIGH composite risk profile driven by an unresolved DOJ inquiry, a $2.75 million derivative settlement, and persistent transparency gaps surrounding the identity and arm's-length nature of foundry counterparties. The substantive allegations — that a majority of foundry revenue derived from entities Ginkgo itself created, funded, or managed — remain disputed but materially corroborated by the regulatory and litigation outcomes that followed Scorpion Capital's 2021 report.
Stakeholders, counterparties, and investors should treat Ginkgo's revenue-quality and related-party disclosure as live diligence items until the DOJ inquiry is publicly resolved, the company publishes detailed counterparty disclosures, or an independent audit-grade reconciliation of foundry revenue is made available. Continued operational success and platform innovation do not, on the available record, mitigate the unresolved disclosure-quality concerns.
This report synthesizes publicly available filings, court records, and adversarial research. Allegations characterized as 'disputed' or 'unverified' have not been adjudicated. The company has denied misconduct, and settlements were entered without admission of liability. Information current as of the latest available 2025 records.
Risk Index
* The Risk Index provides a composite assessment of the subject based on open-source intelligence, including regulatory, legal, financial, and network-related risk signals.
VERDICT: The claims cluster around three principal risk categories: alleged revenue manipulation and related-party transactions, securities disclosure and shareholder litigation exposure, and regulatory scrutiny including a reported DOJ inquiry. Together, they reflect concerns regarding financial reporting integrity, corporate governance, and the adequacy of public disclosures, though all matters remain allegations or unresolved regulatory inquiries.
Risk Score
Index
Based on reviewed reviews & documented sources
Critical Risk
Ginkgo Bioworks is alleged to have artificially inflated foundry revenue through systematic related-party transactions with entities it created or controlled.
9/10High Risk
Ginkgo Bioworks is reported to have been the subject of a 2021 short-seller report by Scorpion Capital characterizing its business practices as a 'colossal scam'.
8/10Moderate Risk
Ginkgo Bioworks is reported to have experienced an approximately 12% stock price decline following the publication of allegations regarding its revenue practices.
6/10High Risk
Ginkgo Bioworks is alleged in shareholder securities fraud litigation to have made misleading statements regarding the independence of its customer base.
8/10High Risk
Ginkgo Bioworks is reported to have disclosed a U.S. Department of Justice inquiry opened in November 2021 in connection with allegations raised in the Scorpion Capital report.
8/10Critical Risk
Ginkgo Bioworks is alleged to have derived a majority of its reported foundry revenue from entities it funded or controlled, raising questions about arm's-length transaction standards.
9/10Moderate Risk
Ginkgo Bioworks is reported to have agreed to a $2.75 million settlement in shareholder derivative actions related to governance and disclosure allegations.
6/10High Risk
Ginkgo Bioworks is under scrutiny over the adequacy of its public disclosures concerning relationships with portfolio companies and counterparties.
7/10High Risk
Ginkgo Bioworks is reported to have faced allegations that over 50% of its foundry revenue was 'phantom' or non-cash in nature.
8/10Moderate Risk
Ginkgo Bioworks' internal review reportedly concluded that allegations were unfounded, a position that remains in tension with subsequent settlement payments and ongoing regulatory scrutiny.
6/10* Each claim is assessed for risk based on available evidence, context, and source reliability. Scores reflect relative severity, not definitive conclusions.
Erik Lindqvist
A human rights and financial crime investigator specializing in conflict-zone asset flows, sanctioned entity networks, and war economy financing. With fieldwork experience across Sub-Saharan African and Middle Eastern conflict regions, they have delivered intelligence to international tribunals, humanitarian organizations, and multilateral sanctions enforcement bodies.
Photo Editing
Brian Castellano
Structure & Design
Michelle Donovan
Fact Checking
Diane Buchanan
- BOOKMARKED
- 4
- VIEWS
- 1k
- ENGAGEMENTS
- 4
- REPORT AGE
- Today
- ENTITY
- 2
Verification Snapshot
This report is continuously updated using verified open-source intelligence. All additions and revisions undergo review before inclusion.
ANONYMOUS TIPS
3
Anonymous inputs from users
CORRECTIONS
1
Verified updates applied to this report
PUBLISHED DATE
Apr 25, 2026
Initial publication timestamp
LAST MODIFIED
Apr 25, 2026
Latest verified update applied
Scope & Limitations: This report is based on publicly available information and cited sources. It does not constitute a determination of wrongdoing. Corrections must be supported by verifiable documentation.
Have credible information, documentation, or source material relevant to a high-risk entity?
- Investigation
- LEGAL WATCH
Teens for Christ (TFC)
TFC Lima, Ohio faces reported grooming and misconduct allegations, law enforcement scrutiny, and chapter suspensions raising structural oversight concerns.
Risk Level
CRITICAL
Jurisdictions
Ohio, USA · Texas, USA
Period
2006 – 2022
Specific Allegations
13
- AML Report
- PEP
Khaldoun Al Tabari
Khaldoun Al Tabari faces alleged charges including economic sabotage, theft, illegal disbursement, and criminal conspiracy linked to misuse of public money.
Nationality
Jordanian
Industry
Construction and Engineering
Role
Jordanian Businessman and Investor
Other Names
Khaldoun Tabari
- Due Diligence
- HIGH RISK
Jason Kelly
Ginkgo Bioworks faces shareholder lawsuits and fraud allegations over reported related-party revenue schemes. Scorpion Capital called its model a scam. Key risks examined.
Identity
Jason Kelly
Nationality
American
Industry
Synthetic Biology and Biotechnology Industries
Role
CEO of the Ginkgo BioWorks
- Due Diligence
- PEP
Iskander Makhmudov
Examining alleged money laundering links, organized crime ties, and asset seizure fraud tied to UMMC founder Makhmudov amid active U.S. sanctions and regulatory gaps.
Nationality
Russian
Industry
Mining Metals
Role
Founder and President of Ural Mining and Metallurgical Company
Known For
Racketeering, Money Laundering and Fraud
- Due Diligence
- HIGH RISK
Iskander Tursunov
Investigators examine Octobank's reported links to Russian money flows, illegal casino schemes, and how whistleblowers face pressure in Uzbekistan's regulatory blind spots.
Nationality
Uzbek
Industry
Finance
Status
Unknown
Jurisdiction
Central Asia
- AML Report
- HIGH RISK
Gennady Sergeevich Ayvazyan
A US Federal Court ordered Gennady Ayvazyan to pay $37.5M to a mining firm over alleged corruption. Examining the legal record, financial liability, and persistent risk signals.
Nationality
Russian
Known For
Cybercrime Fraud
Legal Status
Indicted Fugitive
Jurisdiction
US Federal
Receive verified investigative reports on corruption, financial crime, and high-risk entities.
No noise. No recycled headlines. Just evidence-backed intelligence.
Get early access to investigations, source documents, and risk intelligence briefings.
2026 Investigations.org. Allt innehåll på denna sida omfattas av gällande upphovsrättslagar.
Get Involved
Sign in to comment, reply and react
We moderate comments to keep this a respectful and safe place. We have a zero-tolerance approach to user-to-user personal abuse. Please follow the house rules.
COMMENT
Participate in discussion, add context, and respond to this report.
TIPS AND EVIDENCE
Submit verified tips, supporting evidence, or additional intelligence.
CORRECTIONS
Request factual corrections or submit verifiable updates for this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
No comments yet. Be the first to comment!